Abstract 10047: Diets Low in Sodium and High in Lycopene and Omega-3 Fatty Acids Are Associated with Lower Symptom Burden and Better Quality of Life in Patients with Heart Failure
Background. Most patients with heart failure (HF) are symptomatic despite optimization of medical therapy, which results in decreased quality of life (QOL). There is strong empirical evidence that 3 nutrients (sodium, omega-3 fatty acids, and lycopene) can affect the pathologic pathways (fluid overload, inflammation, and oxidative stress) underlying the common HF symptoms of edema, fatigue, and shortness of air.
Purpose. To determine whether symptom frequency and QOL differed in patients with HF based on dietary sodium, lycopene, and omega-3 fatty acid intake.
Methods. A total of 248 patients with HF (age 61±12 years, 69% male, 45% NYHA class III/IIV, EF 31±13%) completed a 4-day food diary for nutritional intake, Memorial Symptom Assessment Scale_HF for symptom burden, and Minnesota Living with HF questionnaire for QOL. Nutrition Data System-R was used to determine sodium, lycopene, and omega-3 fatty acid intake from food diaries. Patients were grouped according to diet quality: Worst = sodium intake > 3 g and both lycopene and omega-3 fatty acid intake below group median intake. Best = sodium intake < 3 g and both lycopene and omega-3 intake above the median. Poor = one component meeting best criteria. Good = two components meeting best criteria.
Results. Fewer patients in the Best diet group reported having symptoms of fatigue and shortness of air. Patients in the Best diet group had significantly better QOL scores than patients in the Worst diet group. (see Table)
Conclusion. Optimal sodium, lycopene and omega-3-fatty acid intake was associated with less symptom burden and better QOL. The Best diet group contained the smallest number of patients indicating most patients did not spontaneously achieve beneficial dietary levels of all three nutrients. The data suggest that an intervention aimed at improving intake of these nutrients may provide a complementary, nonpharmacolgic approach to decreasing symptoms and improving QOL of patients with HF.
- © 2011 by American Heart Association, Inc.